Use of c-type natriuretic peptide variants to treat osteoarthritis
AssigneeBiomarin Pharmaceutical Inc.
InventorsCharles A. O'Neill, Todd M. Oppeneer, Jason K. Pinkstaff
Life of this patent
Estimating the term…
Abstract
The disclosure relates to the use of variants of C-type natriuretic peptide (CNP) to treat osteoarthritis, to ameliorate one or more symptoms of osteoarthritis, and to treat disorders having an osteoarthritis component.
Claims18
A method of treating osteoarthritis in a subject, comprising intraarticularly administering a composition comprising a C-type natriuretic peptide (CNP) variant to the subject at a dose of from 5 μg/kg to 800 μg/kg of the CNP variant, wherein the CNP variant is selected from the group consisting of:
- (SEQ ID NO:
- 1)
- PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
- (Pro-Gly-CNP37);
- (SEQ ID NO:
- 2)
- GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
- (Gly-CNP37);
- (SEQ ID NO:
- 43)
- QEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC
- [CNP-37(M32N)]
- (SEQ ID NO:
- 44)
- PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
- (Pro-CNP37);
- (SEQ ID NO:
- 45)
- MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
- (Met-CNP37);
- (SEQ ID NO:
- 46)
- GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC
- [Gly-CN P-37(M32N)];
- and
- (SEQ ID NO:
- 47)
- MGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
- (Met-Gly-CNP37).
A method of increasing cartilage growth or slowing cartilage degeneration in a subject having osteoarthritis, comprising intraarticularly administering a composition comprising a C-type natriuretic peptide (CNP) variant to the subject at a dose of from 5 μg/kg to 800 μg/kg of the CNP variant, wherein the CNP variant is selected from the group consisting of:
- (SEQ ID NO:
- 1)
- PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
- (Pro-Gly-CNP37);
- (SEQ ID NO:
- 2)
- GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
- (Gly-CNP37);
- (SEQ ID NO:
- 43)
- QEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC
- [CNP-37(M32N)]
- (SEQ ID NO:
- 44)
- PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
- (Pro-CNP37);
- (SEQ ID NO:
- 45)
- MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
- (Met-CNP37);
- (SEQ ID NO:
- 46)
- GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC
- [Gly-CN P-37(M32N)];
- and
- (SEQ ID NO:
- 47)
- MGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
- (Met-Gly-CNP37).
A method of reducing osteophyte growth in a subject having osteoarthritis or having an injury or trauma in a joint, comprising intraarticularly administering a composition comprising a C-type natriuretic peptide (CNP) variant to the subject at a dose of from 5 g/kg to 800 μg/kg of the CNP variant, wherein the CNP variant is selected from the group consisting of:
- (SEQ ID NO:
- 1)
- PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
- (Pro-Gly-CNP37);
- (SEQ ID NO:
- 2)
- GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
- (Gly-CNP37);
- (SEQ ID NO:
- 43)
- QEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC
- [CNP-37(M32N)]
- (SEQ ID NO:
- 44)
- PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
- (Pro-CNP37);
- (SEQ ID NO:
- 45)
- MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
- (Met-CNP37);
- (SEQ ID NO:
- 46)
- GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC
- [Gly-CN P-37(M32N)];
- and
- (SEQ ID NO:
- 47)
- MGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC
- (Met-Gly-CNP37).
Dependencies are inferred from the claim text.